Document is current
Any future updates will be listed below
-
Authors
Lee, Yan Hiu Athena https://orcid.org/0000-0003-0740-1598
Hui, Jeremy Man Ho https://orcid.org/0000-0003-4512-3138
Leung, Chi Ho https://orcid.org/0000-0001-5484-9390
Tsang, Christopher Tze Wei https://orcid.org/0000-0003-3394-6604
Hui, Kyle
Tang, Pias
Chan, Jeffrey Shi Kai https://orcid.org/0000-0003-0231-2393
Dee, Edward Christopher
Ng, Kenrick https://orcid.org/0000-0001-9132-4075
McBride, Sean
Nguyen, Paul L.
Tse, Gary https://orcid.org/0000-0001-5510-1253
Ng, Chi Fai https://orcid.org/0000-0002-1723-9646
- License Information
-
More Information
Article History
Received: 8 June 2023
Revised: 2 November 2023
Accepted: 9 November 2023
First Online: 5 December 2023
Competing interests
: ECD and SM are funded in part through the Cancer Center Support Grant from the National Cancer Institute (P30 CA008748). SM is also supported by funding from Genentech, Janssen, and Stand-Up-to-Cancer. SM has also collected honorarium from AstraZeneca. PLN received grants and personal fees from Bayer, Janssen, and Astellas and personal fees from Boston Scientific, Dendreon, Ferring, COTA, Blue Earth Diagnostics, Myovant Sciences, and Augmenix outside the submitted work. PLN is also the principal investigator of the NRG-GU009 study.
: The need for patient consent was waived by the Ethics Committee owing to the nature of this study and the use of deidentified data.
